Table 1. Association of gender, neoplasia, metastasis, chemotherapy regimen, number of cycles and ECOG score with HFS.

			HFS		Total	p
			No	Yes
Sex	F	N	15	13	28	0.022a
		%	51.70%	86.70%	63.60%
	M	N	14	2	16
		%	48.30%	13.30%	36.40%
Neoplasm	Pancreas head adenocarcinoma	N	1	1	2	0.636a
		%	3.40%	6.70%	4.50%
	Gastric adenocarcinoma	N	1	0	1
		%	3.40%	0.00%	2.30%
	Gall bladder adenocarcinoma	N	2	0	2
		%	6.90%	0.00%	4.50%
	Cholangiocarcinoma	N	1	0	1
		%	3.40%	0.00%	2.30%
	Colon neoplasm	N	8	3	11
		%	27.60%	20.00%	25.00%
	Breast neoplasm	N	9	7	16
		%	31.00%	46.70%	36.40%
	Rectum neoplasm	N	7	3	10
		%	24.10%	20.00%	22.70%
	Sigmoid neoplasm	N	0	1	1
		%	0.00%	6.70%	2.30%
Metastasis	Yes	N	11	6	17	0.894a
		%	37.90%	40.00%	38.60%
	No	N	18	9	27
		%	62.10%	60.00%	61.40%
Chemotherapy scheme	Capecitabine + oxaliplatin	N	9	3	12	0.500b
		%	31.00%	20.00%	27.30%
	Capecitabine	N	20	12	32
		%	69.00%	80.00%	72.70%
No. of cycles	1–3	N	17	7	24	0.415a
		%	58.60%	46.70%	54.50%
	4–6	N	8	7	15
		%	27.60%	46.70%	34.10%
	>6	N	4	1	5
		%	13.80%	6.70%	11.40%
ECOG-PS baseline before treatment	0	N	0	4	4	0.000a
		%	0.00%	26.70%	9.10%
	1–2	N	28	6	34
		%	96.60%	40.00%	77.30%
	3–4	N	1	5	6
		%	3.40%	33.30%	13.60%

^aChi-square test

^bFisher’s exact test